NGM BIOPHARMACEUTICALS INC Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019
ASSETS
Current assets:
Cash and cash equivalents
Short-term marketable securities
Related party contract asset
Related party receivable from collaboration
Prepaid expenses and other current assets
Restricted cash
Total current assets
Property and equipment, net
Operating lease right-of-use asset
Restricted cash
Deferred IPO costs
Other non-current assets
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued liabilities
Operating lease liability, current
Deferred rent, current
Contract liabilities
Total current liabilities
Operating lease liability, non-current
Deferred rent, non-current
Early exercise stock option liability
Other non-current liabilities
Total liabilities
Convertible preferred stock, $0.001 par value; 96,268,206 shares authorized; zero and 47,267,466 shares issued and outstanding as of December 31, 2019 and 2018, respectively
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and 2022, respectively
Common stock, $0.001 par value; 400,000 shares authorized; 82,907 and 81,885 shares issued and outstanding as of December 31, 2023 and 2022, respectively
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders' equity
Total liabilities, convertible preferred stock and stockholders' deficit
Total liabilities, convertible preferred stock and stockholders' equity (deficit)
Total liabilities and stockholders' equity

Comments